January 8, 2010
LOS ANGELES, January 08, 2010 – KYTHERA Biopharmaceuticals, Inc. ("Kythera"), is scheduled to present at the J.P. Morgan 28th Annual Healthcare Conference, at 3:30 p.m. Pacific Time on Tuesday, January 12, 2010 at the Westin St. Francis in San Francisco, CA. Keith Leonard, President and CEO, will be presenting on behalf of KYTHERA and will cover company strategy and progress on the research and development pipeline.
“We look forward to participating in this premier healthcare conference and providing an update to the investment community,” said Keith Leonard, President and CEO. “During 2009, we announced and presented positive data from two Phase 2 trials with ATX-101, a first-in class injectable drug for the reduction of small volumes of fat. Additionally, we initiated a first-in-human pilot trial for ATX-104, a light-activated facial contouring agent and a proof-of-concept trial for ATX-202, a novel agent for pigmentation modulation.
KYTHERA’s presentation will be available to view online for seven days in the Newsroom at www.kytherabiopharma.com following the live presentation.